100.00% -0.0129

Nls Pharmaceutics Ag (NLSPW)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Nls Pharmaceutics Ag Stock (NLSPW) Company Profile

Nls Pharmaceutics Ag

Healthcare (1161)

Biotechnology (676)

41 44 512 21 50

The Circle 6, Zurich

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NLSPW's Discussions on Twitter

Vergleichen Sie NLSPW mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NLSPW Nls Pharmaceutics Ag	0.00	0	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

Nls Pharmaceutics Ag Aktie (NLSPW) Neueste Nachrichten

Finanzdaten der Nls Pharmaceutics Ag-Aktie (NLSPW)

Es liegen keine Finanzdaten für Nls Pharmaceutics Ag (NLSPW) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Nls Pharmaceutics Ag (NLSPW)

Nls Pharmaceutics Ag Stock (NLSPW) Company Profile

Vergleichen Sie NLSPW mit anderen Aktien

Nls Pharmaceutics Ag Aktie (NLSPW) Neueste Nachrichten

NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider.com

NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa

NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India

NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World

NLS Pharmaceutics announces merger with Kadimastem - Investing.com India

NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com UK

NLS Pharmaceutics CEO Issues Letter to Shareholders - Yahoo Finance

Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com

NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa

NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com India

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - accessnewswire.com

NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire

AEX-2 increases total wake duration in mouse model - BioWorld Online

NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire

NLS Pharmaceutics reports progress in narcolepsy treatment By Investing.com - Investing.com South Africa

NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com

Pre-IND meeting guides path forward for ITOL-102 for type 1 diabetes - BioWorld Online

NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - Yahoo Finance

NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire

NLS Pharmaceutics And Kadimastem Unveil Multi-Target Diabetes Approach - Nasdaq

Is NLSP’s price to cash per share ratio a concern for investors? - US Post News

NLS Pharmaceutics (NLSP) Shares Surge As Market Reacts To Potential Merger - Stocks Telegraph

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - Marketscreener.com

Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews

Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews

NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference - ACCESS Newswire

Dow Edges Lower; Exxon Mobil Earnings Top Views - Benzinga

NLS Pharmaceutics Says Kadimastem Shareholders Approve Merger With NLS; Shares Rise - Marketscreener.com

Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings - Benzinga India

NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice - ACCESS Newswire

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics -January 31, 2025 at 07:31 am EST - Marketscreener.com

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Marketscreener.com

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Benzinga

NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions - ACCESS Newswire

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - ACCESS Newswire

Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance - ACCESS Newswire

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing - ACCESS Newswire

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform - ACCESS Newswire

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - ACCESS Newswire

NLS Pharmaceutics Announces Company Update on Strategic Partnerships - ACCESS Newswire

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - ACCESS Newswire

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering - ACCESS Newswire

NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - ACCESS Newswire

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge - ACCESS Newswire

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS - Marketscreener.com

SEC Form 425 filed by NLS Pharmaceutics Ltd. - Quantisnow

Finanzdaten der Nls Pharmaceutics Ag-Aktie (NLSPW)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie NLSPW